Straight to the Shot: A New Way to Quit Fentanyl and Start Buprenorphine

Fentanyl changed the playbook for starting buprenorphine, and we’re tired of watching people suffer through days of withdrawal just to “earn” their first dose. So we break down a cleaner, faster on-ramp: direct-to-inject. Think of weekly Brixadi as an automatic microdose that builds buprenorphine levels over 24 hours, cuts out guesswork, and sets up a smooth handoff to a monthly injection that actually sticks.

We start by demystifying precipitated withdrawal with simple, memorable analogies—the “100 mph to 60 mph” shift explains why heroin-era inductions no longer work when fentanyl lingers like THC. From there, we map the current options: long waits with comfort meds, meticulous sublingual microdosing, short-acting opioid bridges, and why DTI often outperforms them in the real world. You’ll hear our step-by-step protocol for week one: when to keep using, when to stop, how to layer sublingual buprenorphine, and which comfort meds reliably blunt symptoms without fogging people out.

Then we get tactical. We compare Sublocade and Brixadi in plain English—needle size, injection sites, refrigeration, and the “tail” that can protect patients who miss appointments or face custody interruptions. We explain why some teams favor weekly Brixadi for the bridge and monthly Sublocade for its long half-life, while others choose monthly Brixadi for logistics and patient comfort. We also clear up a big myth: yes, you can supplement injectables with sublingual buprenorphine when needed.

What matters most is the outcome. DTI compresses complexity into a single, supported action and replaces fear with momentum. Patients report fewer false starts, less chaos, and a quicker path to cravings control and stability. For clinicians and outreach teams, it’s a protocol that works on the street and in clinic, with clear timing, meds, and contingencies that honor how people actually live.

If this helped you rethink induction in the fentanyl era, follow the show, share it with a colleague, and leave a quick review so more clinicians and families can find it. Treating addiction saves lives—let’s make the first step easier.

To contact Dr. Grover: ammadeeasy@fastmail.com